(Q41704964)

English

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

scientific article published on October 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 October 2017

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group (English)

1 reference

Europe PubMed Central

7 October 2017

multicenter clinical trial

0 references

author name string

B Thürlimann

1

1 reference

Europe PubMed Central

7 October 2017

R Paridaens

2

1 reference

Europe PubMed Central

7 October 2017

D Serin

3

1 reference

Europe PubMed Central

7 October 2017

J Bonneterre

4

1 reference

Europe PubMed Central

7 October 2017

H Roché

5

1 reference

Europe PubMed Central

7 October 2017

R Murray

6

1 reference

Europe PubMed Central

7 October 2017

E di Salle

7

1 reference

Europe PubMed Central

7 October 2017

S Lanzalone

8

1 reference

Europe PubMed Central

7 October 2017

M G Zurlo

9

1 reference

Europe PubMed Central

7 October 2017

G Piscitelli

10

1 reference

Europe PubMed Central

7 October 2017

publication date

1 October 1997

1 reference

Europe PubMed Central

7 October 2017

European Journal of Cancer

1 reference

Europe PubMed Central

7 October 2017

33

1 reference

Europe PubMed Central

7 October 2017

11

1 reference

Europe PubMed Central

7 October 2017

1767-1773

1 reference

Europe PubMed Central

7 October 2017

Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel irreversible aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New endocrine therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900283-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(97)00283-9

1 reference

Europe PubMed Central

7 October 2017

1 reference

Europe PubMed Central

7 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41704964&oldid=1926085841"